Biomarin Pharmaceutical (BMRN) FY2024 results: revenue $2.9 billion, up 18.0% on the year
Biomarin Pharmaceutical Inc. (BMRN) reported revenue of $2.9 billion for fiscal 2024, the year ended 31 December 2024, up 18.0% on the year before. Net income was $427 million, up 154.6%, and diluted earnings per share $2.21. The figures are the company's own, from the 10-K it filed with the SEC on 24 February 2025.
Revenue
$2.9 billion
+18.0% on the year
FY2017FY2024
Operating margin
17.0%
7.7% a year earlier
FY2017FY2024
Net income
$427 million
+154.6% on the year
FY2017FY2024
Diluted EPS
$2.21
+154.0% on the year
FY2017FY2024
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2024
FY2023
FY2022
On the year
Last 8 years
Operating cash flow
573
159
176
+259.7%
Capital expenditure
85.4
96.7
121
-11.7%
Free cash flow
487
62.6
54.9
+679.0%
Free cash flow margin
17.1%
2.6%
2.6%
Cash from investing
136
-111
-20.0
Cash from financing
-526
-18.7
-18.6
Depreciation and amortisation
96.4
104
102
-7.6%
Share-based compensation
202
207
196
-2.7%
Buybacks
n/a
n/a
0.0
Diluted shares, weighted
197m
192m
189m
+2.7%
Shares outstanding at period end
191m
189m
186m
+1.1%
Balance sheet
$ million
FY2024
FY2023
FY2022
On the year
Last 8 years
Shareholders' equity
5,658
4,952
4,603
+14.3%
Debt
595
1,087
1,083
-45.2%
Operating lease liabilities
30.5
38.0
26.3
-19.8%
Finance lease liabilities
0.8
0.1
0.2
+881.8%
Other liabilities
705
765
662
-7.9%
Total liabilities and equity
6,989
6,842
6,375
+2.2%
Fixed assets
1,043
1,066
1,073
-2.2%
Goodwill
196
196
196
0.0%
Intangible assets
255
295
339
-13.4%
Investments
716
930
901
-23.0%
Cash and equivalents
943
755
725
+24.9%
Receivables
661
634
461
+4.2%
Inventory
1,233
1,107
894
+11.3%
Other assets
1,942
1,859
1,786
+4.5%
Total assets
6,989
6,842
6,375
+2.2%
10-K for the year ended 31 December 2024, filed 24 February 2025: the filing.